Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 39Carcinoma, Hepatocellular 38Small Cell Lung Carcinoma 26Breast Neoplasms 19Neoplasms 18Cholangiocarcinoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 15Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Esophageal Neoplasms 8Carcinoma, Renal Cell 8Stomach Neoplasms 7Head and Neck Neoplasms 7Carcinoma, Transitional Cell 7Prostatic Neoplasms 6Melanoma 6Endometrial Neoplasms 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Neoplasms by Site 5Mesothelioma, Malignant 5Adenocarcinoma 5

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Biliary Tract Cancer × durvalumab × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡